New antibacterial pharmacophore analysis
MoA
A pharmacophore is the common subunit of active molecules that interact with biological targets. It is crucial to develop new antibacterial drugs with new MoA and/or pharmacophores to slow down drug resistance and to potentially allow the identification of new combination therapies. This is also why there is considerable excitement around the potential of non-traditional antibacterials, along with the yet-to-be-proven hypothesis that some modalities, such as antivirulence strategies, will not lead to resistance since bacterial survival is not directly targeted [In this review, new pharmacophores not previously found in human antibacterial drugs have been analyzed as a measure of antibacterial structure innovation (Table Existing antibacterial classes that inhibit the bacterial cell envelope include the BL, glycopeptide, polymyxin, daptomycin (lipopeptide), fosfomycin, and cycloserine classes. The new cell envelope acting antibacterials inhibit several different targets (LptD: murepavadin (The (fluoro)quinolone class are DNA synthesis inhibitors (DNA gyrase GyrA and topoisomerase IV parC [Bacterial protein synthesis inhibition can be caused by several compound classes including macrolides, aminoglycosides, tetracyclines, lincosamides, chloramphenicol, oxazolidinones, pleuromutilins and fusidic acid. There are two oxaborole-type leucine tRNA synthetase (LeuRS) inhibitors, epetraborole (There are two direct-acting traditional and five non-traditional antibacterial compounds with new mechanisms. Telacebec (